[
  {
    "ts": null,
    "headline": "Amgen (AMGN) Outperforms Broader Market: What You Need to Know",
    "summary": "The latest trading day saw Amgen (AMGN) settling at $296.85, representing a +2.18% change from its previous close.",
    "url": "https://finnhub.io/api/news?id=f41f7a9e25bc4ce77e572114fbe94c2e5ef143e33093e753d9b2566c68e3cc05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751493003,
      "headline": "Amgen (AMGN) Outperforms Broader Market: What You Need to Know",
      "id": 135721386,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The latest trading day saw Amgen (AMGN) settling at $296.85, representing a +2.18% change from its previous close.",
      "url": "https://finnhub.io/api/news?id=f41f7a9e25bc4ce77e572114fbe94c2e5ef143e33093e753d9b2566c68e3cc05"
    }
  },
  {
    "ts": null,
    "headline": "July Dog Of The Dow's 'Safer' Buy: Verizon",
    "summary": "Verizon Communications Inc. stands out as the top Dow dividend pick with strong cash flow and value potential. Click for my analysis and why I like VZ.",
    "url": "https://finnhub.io/api/news?id=8925dda184e2b9957f67d5da8f9ed43de30abb890049f9b7f766093e43a0a1fa",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751476862,
      "headline": "July Dog Of The Dow's 'Safer' Buy: Verizon",
      "id": 135716420,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2181800802/image_2181800802.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Verizon Communications Inc. stands out as the top Dow dividend pick with strong cash flow and value potential. Click for my analysis and why I like VZ.",
      "url": "https://finnhub.io/api/news?id=8925dda184e2b9957f67d5da8f9ed43de30abb890049f9b7f766093e43a0a1fa"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
    "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=005644e3c3b92157e08b2496feb84995a09efb3a1fc2560ad869f40fbe1fd6ed",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751474100,
      "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
      "id": 135731744,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=005644e3c3b92157e08b2496feb84995a09efb3a1fc2560ad869f40fbe1fd6ed"
    }
  },
  {
    "ts": null,
    "headline": "mAbxience Announces European Commission Approval of Denosumab Biosimilars",
    "summary": "mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the European Commission has granted approval for its denosumab biosimilars Denbrayce速 and Izamby速. This approval follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) and represents a major milestone in mAbxience's mission to provide high-quality, accessible, and affordable therapies worldwide.",
    "url": "https://finnhub.io/api/news?id=75e55e8aaca510bfd837f5e59772b2fa15c48ccd70d3e6ce25bcdf24ac49506e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751461200,
      "headline": "mAbxience Announces European Commission Approval of Denosumab Biosimilars",
      "id": 135711266,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the European Commission has granted approval for its denosumab biosimilars Denbrayce速 and Izamby速. This approval follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) and represents a major milestone in mAbxience's mission to provide high-quality, accessible, and affordable therapies worldwide.",
      "url": "https://finnhub.io/api/news?id=75e55e8aaca510bfd837f5e59772b2fa15c48ccd70d3e6ce25bcdf24ac49506e"
    }
  },
  {
    "ts": null,
    "headline": "Fresenius Expands Biosimilars Portfolio With The Launch of Denosumab Biosimilars in the U.S.",
    "summary": "in the United States.'Fresenius Kabi is very pleased to continue the consistent launches of new biosimilars for U.S. patients, providers and payors,' said Dr. Sang Jin Pak, President Fresenius Kabi...",
    "url": "https://finnhub.io/api/news?id=c14a47346730754a178508128395122fc4bdbcb92a399e6c5f15457d479d88e5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751450717,
      "headline": "Fresenius Expands Biosimilars Portfolio With The Launch of Denosumab Biosimilars in the U.S.",
      "id": 135712157,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "in the United States.'Fresenius Kabi is very pleased to continue the consistent launches of new biosimilars for U.S. patients, providers and payors,' said Dr. Sang Jin Pak, President Fresenius Kabi...",
      "url": "https://finnhub.io/api/news?id=c14a47346730754a178508128395122fc4bdbcb92a399e6c5f15457d479d88e5"
    }
  },
  {
    "ts": null,
    "headline": "This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk",
    "summary": "Amgen recently released the full data from a trial involving its GLP-1 drug, MariTide.  More than one-quarter of the participants on the highest dosage of the drug had to stop taking it due to adverse side effects.  There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs.",
    "url": "https://finnhub.io/api/news?id=a42bf488a4b5bd9da21e125631a47e29392ed7ccfebd714b00255a8002f14d4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751418840,
      "headline": "This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk",
      "id": 135703109,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen recently released the full data from a trial involving its GLP-1 drug, MariTide.  More than one-quarter of the participants on the highest dosage of the drug had to stop taking it due to adverse side effects.  There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs.",
      "url": "https://finnhub.io/api/news?id=a42bf488a4b5bd9da21e125631a47e29392ed7ccfebd714b00255a8002f14d4d"
    }
  }
]